TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Plus Ontak in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Melanoma with evidence of metastatic disease~* Life expectancy of at least 12 weeks.~* Karnofsky performance status index of greater than or equal to 80%.~* Adequate hematopoietic, renal, and hepatic function, defined as:~* Patient must express HLA-A2~* Tumor biopsy: patient must agree to undergo biopsy of accessible tumor before and after therapy, when feasible, to study tumor cell properties and characteristics of immune cells.~* EKG without evidence of arrhythmia or changes that indicate acute ischemia.~* Pulse oximetry showing oxygen saturation of at least 90% on room air.~Exclusion Criteria:~* Significant cardiovascular disease, or cardiac arrhythmia requiring medical intervention.~* Pregnant or nursing women.~* Biological therapy in the 4 weeks prior to the start of dosing.~* Patients with intrinsic immunosuppression, including seropositivity for HIV antibody.~* Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis C.~* Concurrent systemic corticosteroids (except physiologic replacement doses)or other immunosuppressive drugs (eg. cyclosporin A).~* Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent.~* Active or history of autoimmune disease~* Active gastrointestinal bleeding or uncontrolled peptic ulcer disease.~* Presence of untreated brain metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine Alone (Type: EXPERIMENTAL): Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
- Vaccine plus Ontak (Type: EXPERIMENTAL): Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability to give informed consent~* Lower urinary tract symptoms (LUTS) felt to be secondary to bladder outlet obstruction from benign prostatic hyperplasia~* Maximum urinary flow rate \< 15 ml/sec, voided volume ≥ 125 cc~* American Urological Association symptom score ≥ 9~* Transrectal ultrasound determined prostate volume ≤ 60 cc~Exclusion Criteria:~* Inability to give informed consent~* Maximum urinary flow rate ≥ 15 ml/sec~* Transrectal ultrasound determined prostate volume \> 60cc~* AUA symptom score \< 9~* Active urinary tract infection~* Bleeding diathesis~* Neurological disease that is felt to affect the bladder or a history of a neurogenic or chronically decompensated bladder~* Known prostate cancer~* Active bladder cancer (within the last 2 years)~* Prostate specific antigen (PSA) \> 4.0 unless previous negative biopsy~* Urinary retention~* Post-void residual (PVR) \> 300 cc

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Comparison study between KTP and HoLAP procedures for BPH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health Literacy for Children With Atopic Dermatitis and Their Caregivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New clinical diagnosis of pediatric atopic dermatitis, or existing atopic dermatitis but new patient to MU dermatology~* Age 7 or under~Exclusion Criteria:~* Age 8 or above

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Physician/resident instruction (Type: NO_INTERVENTION): This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
- Nurse instruction (Type: ACTIVE_COMPARATOR): Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimers disease, regardless of date of diagnosis relative to study entry date.~* Has an Alzheimers disease status of mild to moderate, as classified by a Mini Mental State Examination (MMSE) score of 16 - 26 inclusive at screening.~* Post-menopausal females defined as menopause is defined as \>6 months without menstrual period with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However if indicated this should be confirmed by oestradiol and FSH levels consistent with menopause (according to local laboratory ranges).~* Women who are on HRT (hormone replacement therapy) treatment, and have not been confirmed as post-menopausal should be advised to use contraception.~* Has a permanent caregiver who is willing to attend all visits, oversee the subjects compliance with protocol-specified procedures and study medication, and report on subjects status. (Subjects living alone or in a nursing home are not eligible).~Exclusion Criteria:~* Has a history of or suffers from claustrophobia.~* Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for at least 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis).~* Has a history or presence of other neurological or other medical conditions that may influence the outcome or analysis of the PET scan results. Examples of such conditions include, but are not limited to stroke, traumatic brain injury, epilepsy or space occupying lesions.~* History of Type I or Type II diabetes mellitus.~* Fasting plasma glucose level \>126 mg/dL (\>7.0 mmol/L) or HbA1c \>6.2%.~* History or clinical/laboratory evidence of moderate congestive heart failure defined by the New York Heart Association criteria (class II-IV.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Rosi XR (Type: EXPERIMENTAL): Rosi XR
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (matched)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypertension in Hemodialysis Patients (Aim 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients on chronic hemodialysis for \> 3 mos.~2. Compliance with hemodialysis treatments as defined by less than one missed dialysis per month~3. Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) \>135/75 mm Hg after participation in the ultrafiltration (UF) Trial, or those on no antihypertensive medications but unwilling to do UF Trial.~4. Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) \>104 g/m2 in women and \>116 g/m2 in men.~5. Willingness to give informed consent.~Exclusion criteria:~1. Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months~2. Noncompliance with hemodialysis treatments~3. Known drug abuse~4. Chronic obstructive pulmonary disorder (COPD) requiring home oxygen~5. Congestive Heart Failure Class III or IV.~6. Body mass index \> 40 kg/m2.~7. Known contraindication to atenolol (severe heart failure, bradycardia, bronchial asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or allergy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Atenolol
- 2 (Type: EXPERIMENTAL): Lisinopril

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paricalcitol Over Vessel Wall

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 50 and 75 years.~* Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).~* Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.~* Plasma concentrations of 25 (OH) vitamin D \<30 ng/ml.~* Without vitamin D supplementation for 3 months before the study.~* Serum P\> 3.8 mg / dl.~* Serum Ca\> 9.8 mg / dl.~* No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).~* No exclusion criteria for the use of contrast.~Exclusion Criteria:~* Allergic reaction to sulfur hexafluoride.~* Recent unstable cardiac symptoms.~* Patients with recent coronary intervention (\<7 days)~* Patients with class III and IV heart failure or severe arrhythmias.~* Severe pulmonary hypertension.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patient will take one pill of paricalcitol a day.
- Usual treatment. (Type: NO_INTERVENTION): Patient allocated to this arm will only take his/her habitual treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Shanghai Registry of Acute Coronary Events

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment~Exclusion Criteria:~* non ACS patients;~* complicated with other lethal disease~* predicted life span less than 12 months~* known allergy history to any anti-platelet or anti-thrombin medicine~* unconscious at the time of arrival at the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
- 2 (Type: None): patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
- 3 (Type: None): patients with non-ST-elevation ACS treated by immediate PCI
- 4 (Type: None): patients with non ST-elevation ACS treated by elective PCI
- 5 (Type: None): STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
- 6 (Type: None): STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Post-Operative Analgesic Effects of Local Wound Infiltration With Ketorolac After Inguinal Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 75 years old undergoing elective unilateral inguinal herniorrhaphy at Ramathibodi hospital~* Patients who are ASA classification 1-2~* Patients who had normal liver function test : AST 5-34 U/L , ALT 0-55 U/L, ALP 40-150 U/L ,TB0.2-1.2 mg/dL ,DB 0.0-0.5 mg/dL~* Patients who are going the operation under general anesthesia~* Patients who undergoing herniorrhaphy with Lichtenstein Tension-Free Repair technique~Exclusion Criteria:~* Patients who had femoral hernia~* Patients who had history of NSAIDs allergy~* Patients with history of prior hernorrhaphy~* Patients who had history of GI bleeding and gastritis~* Patients who had infection~* Patients who had history of SLE, HIV, asthma , cardiovascular disease and chronic kidney disease(GFR\<60 ml/min/1.73m2)~* Patients with end stage disease~* Patients who are pregnant~* Patients who reject or withdrawal from research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ketorolac injections (Type: EXPERIMENTAL): Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
- bupivacaine (Type: ACTIVE_COMPARATOR): Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EXALT: EXercise Attenuates Liver Tumors Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age \>=18 or \<70 years~* Liver transplant candidates (under evaluation or listed for transplant with HCC)~* Hepatocellular Carcinoma diagnosis (HCC)~* Complete response to LRT~Exclusion Criteria:~* Active cardiac symptoms~* BMI \<18 or \>45 kg/m2(16)~* CPT Class B or C liver disease~* ECOG \>2~* Hepatic decompensation~* Institutionalized/prisoner~* Pregnancy~* Severe medical comorbidities/psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Exercise intervention (Type: EXPERIMENTAL): The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
- Standard of Care (Type: NO_INTERVENTION): Subjects are instructed to maintain their current activity level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of multiple myeloma less than 12 months since initiation of systemic therapy~* Age ≥60 years at time of transplantation~* KPS 70-100%~* Recovery from complications of prior therapy~Exclusion Criteria:~* Diagnosis other than multiple myeloma~* Chemotherapy or radiotherapy within 8 days of initiating treatment in this study~* Prior dose-intense therapy within 56 days of initiating treatment in this study~* Uncontrolled bacterial, viral, fungal or parasitic infections~* Uncontrolled CNS metastases~* Known amyloid deposition in heart~* Organ dysfunction~* LVEF \<40% or cardiac failure not responsive to therapy~* FVC, FEV1 or DLCO \< 40% of predicted and/or receiving supplementary continuous oxygen~* Evidence of hepatic synthetic dysfunction or total bilirubin \> 2x or AST \> 3x ULN~* Measured creatinine \< 20ml/min~* Sensory peripheral neuropathy grade 4 within 14 days of enrollment~* Karnofsky score \< 70%~* Life expectancy limited by other co-morbid illnesses

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).
- Treatment Arm B (Type: EXPERIMENTAL): Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically node negative operable breast cancer~* No prior incision or excision biopsy~Exclusion Criteria:~* Palpable axillary lymph nodes~* Contraindications for injecting radiocolloid

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Radio guided Sentinle node biopsy (Type: EXPERIMENTAL): The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility